Great Lakes Advisors LLC increased its holdings in shares of Novartis AG (NYSE:NVS) by 4.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 17,586 shares of the company’s stock after buying an additional 740 shares during the period. Great Lakes Advisors LLC’s holdings in Novartis were worth $1,515,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stelac Advisory Services LLC bought a new stake in shares of Novartis during the third quarter worth approximately $113,000. Columbia Asset Management bought a new stake in shares of Novartis during the third quarter worth approximately $126,000. Belpointe Asset Management LLC bought a new stake in shares of Novartis during the third quarter worth approximately $131,000. Resources Management Corp CT ADV bought a new stake in shares of Novartis during the third quarter worth approximately $142,000. Finally, Howe & Rusling Inc. raised its stake in shares of Novartis by 50.9% during the third quarter. Howe & Rusling Inc. now owns 1,705 shares of the company’s stock worth $147,000 after buying an additional 575 shares during the last quarter. 11.20% of the stock is owned by institutional investors and hedge funds.

A number of equities research analysts recently weighed in on NVS shares. Goldman Sachs Group raised shares of Novartis from a “neutral” rating to a “conviction-buy” rating in a research note on Friday, November 16th. Bank of America upgraded shares of Novartis from an “underperform” rating to a “buy” rating and set a $74.71 price objective for the company in a report on Monday, September 10th. Zacks Investment Research cut shares of Novartis from a “hold” rating to a “sell” rating in a report on Wednesday, August 29th. JPMorgan Chase & Co. restated a “neutral” rating on shares of Novartis in a report on Thursday, October 18th. Finally, Cowen upgraded shares of Novartis from a “market perform” rating to an “outperform” rating and set a $88.03 price objective for the company in a report on Sunday. Eleven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $85.91.

Shares of NYSE NVS opened at $90.77 on Thursday. The company has a market cap of $209.68 billion, a P/E ratio of 18.87, a PEG ratio of 2.01 and a beta of 0.74. The company has a quick ratio of 0.96, a current ratio of 1.20 and a debt-to-equity ratio of 0.29. Novartis AG has a 52-week low of $72.30 and a 52-week high of $94.19.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, October 18th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.01. The firm had revenue of $12.78 billion during the quarter, compared to analysts’ expectations of $12.88 billion. Novartis had a net margin of 25.98% and a return on equity of 15.81%. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.29 earnings per share. As a group, equities research analysts predict that Novartis AG will post 5.17 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Great Lakes Advisors LLC Acquires 740 Shares of Novartis AG (NVS)” was first posted by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/great-lakes-advisors-llc-acquires-740-shares-of-novartis-ag-nvs/2665218.html.

Novartis Company Profile

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Read More: What is an investor looking for in an SEC filing?

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.